XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers

NCT ID: NCT03441815

Last Updated: 2018-02-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 28 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-14
• Study Completion Date: 2015-07-07

Brief Summary

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety and tolerability of increasing doses of XC8 after single and repeated oral administration in healthy volunteers. The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

The primary objective of the study was to evaluate the safety and tolerability profile for XC8 after single and multiple administration based on the frequency and severity of adverse events and changes in vital signs, laboratory results, electrocardiography and results of the physical examination.

The secondary objective of the study was to assess pharmacokinetics of XC8.

Detailed Description

One Russian center was approved for participation in this study. One center was initiated. Healthy volunteers were enrolled in 1 center. The study consisted of 4 periods: screening, single administration, multiple administration and follow-up.

All eligible subjects were randomized into the study in appropriate cohort groups sequentially.

Cohort 1 - XC8 or Placebo 2 mg once and then daily 14 days after a 6-day break; Cohort 2 - XC8 or Placebo 10 mg once and then daily during 14 days after a 6-day break; Cohort 3 - XC8 or Placebo 50 mg once and then daily during 14 days after a 6-day break; Cohort 4 - XC8 or Placebo 200 mg once and then daily during 14 days after a 6-day break.

The decision regarding increasing of the study drug dose for a subsequent cohort was made by the Data Safety Monitoring Committee on the basis of preliminary safety results assessment.

A total of 20 volunteers received XC8 (2 mg, 10 mg, 50 mg or 200 mg) and a total of 8 volunteers received the placebo during the study participation. The follow-up period lasted for 4 weeks.

Conditions

Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

XC8 2 mg

Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).

Group Type: EXPERIMENTAL

XC8

Intervention Type: DRUG

XC8 10 mg

Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).

Group Type: EXPERIMENTAL

XC8

Intervention Type: DRUG

XC8 50 mg

Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).

Group Type: EXPERIMENTAL

XC8

Intervention Type: DRUG

XC8 200 mg

Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).

Group Type: EXPERIMENTAL

XC8

Intervention Type: DRUG

Placebo

Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Interventions

XC8

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Other Intervention Names

Histamine glutarimide

Eligibility Criteria

Inclusion Criteria

1. Non-smoking men aged 18 to 50 years (inclusive);

2. Verified diagnosis "healthy" according to standard clinical, laboratory and instrumental methods of examination;

3. Body mass index of 19 to 30 kg/m2 (inclusive);

4. Consent to use reliable methods of contraception during the study and 3 months after its completion (condoms with spermicide);

5. Signed patient information sheet and informed consent form for participation in the study.

Exclusion Criteria

1. Hepatic disorder or renal disease; any other disease that, in the opinion investigator, may affect the results of the study, or may lead to the health aggravation during the study;

2. Laboratory abnormalities at screening;

3. Course intake of medicinal products (including herbs and biologically active additives) for preventive or curative purposes within 1 month prior to screening;

4. Antibodies to HIV and hepatitis C virus, the presence of the hepatitis B surface antigen, a positive syphilis test;

5. The presence of a sleep disorder (for example, night work, sleep disturbances, insomnia, recent return from another time zone, etc.);

6. Signs of alcohol or drug abuse; taking alcohol or drugs during 4 days before screening;

7. History of allergies (including medicines and food products);

8. Symptomatic rhinitis in anamnesis during 2 years prior to screening (allergic rhinitis, non-allergic rhinitis or pollinosis);

9. Blood donation / plasma, surgical intervention (in a hospital environment) during 12 weeks before screening;

10. Participation in other clinical trials or taking the study drug during 3 months before screening;

11. Impossibility to understand or follow protocol instructions;

12. Smoking 3 months before screening;

13. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption;

14. Acute infectious diseases less than 4 weeks before the start of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

PHARMENTERPRISES LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

SBEI HPE The First Moscow State Medical University n.a. Sechenov of Ministry of Health of Russian Federation, University Hospital #2, Department of Development of New Medicines

Moscow, , Russia

Countries

Russia

Other Identifiers

PULM-XC8-01

Identifier Type: -

Identifier Source: org_study_id